Skip to main content

Advertisement

SpringerLink
Log in

Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

We aimed to assess the immunogenicity of a single half-dose of AS03-adjuvanted monovalent 2009 pandemic H1N1 vaccine in healthy adults. Healthy subjects age 20–60 years were prospectively enrolled in a cohort receiving intramuscular administration of a single half-dose (1.875 μg of hemagglutinin [HA]) of adjuvanted 2009 pandemic H1N1 influenza vaccine. Data from participants enrolled in a concomitant study of immunogenicity following a full-dose (3.75 μg of HA) are presented concurrently. Sera for assessment of hemagglutination-inhibiting (HAI) antibody to the vaccine strain were obtained before and 14 or 21 days after vaccination. Ninety-seven participants received a half-dose and 50 received a full-dose of vaccine. In the half-dose cohort, Food and Drug Administration criteria for immunogenicity regarding seroprotection and seroconversion rates were met for subjects aged 20–45 years, but not for those aged 46–60 years. There was no statistically significant difference in the proportion of individuals achieving a post-vaccination HAI titre of ≥1:40, the geometric mean titres of post-vaccination antibody, or the proportion of individuals with a four-fold or greater increase in antibody levels between the two cohorts. Participants 46–60 years of age were significantly less likely to be seroprotected at day 21 than those 20–45 years old in both cohorts. Immunogenicity of a half dose of adjuvanted pH1N1 influenza vaccine was adequate in subjects aged 20–45 years. Dose reduction is a possible strategy for expanding the availability in the event of vaccine shortage in this age group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Nichol KL (2008) Efficacy and effectiveness of influenza vaccination. Vaccine 26(Suppl 4):D17–D22

    Article  PubMed  CAS  Google Scholar 

  2. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E (2010) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 7:CD001269

    PubMed  Google Scholar 

  3. Hebert PC, MacDonald N (2009) The H1N1 vaccine race: can we beat the pandemic? CMAJ 181(8):E125–E127

    Article  PubMed  Google Scholar 

  4. Eggertson L (2009) Canada can release pandemic vaccine earlier if necessary, chief public health officer says. CMAJ 181(10):E225–E226

    Article  PubMed  Google Scholar 

  5. Health Canada. Health Canada approves pandemic H1N1 flu vaccine for Canadians. Health Canada news release 2009–171, October 21, 2009. Available at: http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2009/2009_171-eng.php. Accessed 04 September 2010

  6. CBC News. H1N1 flu shots begin in Ontario. Available at: http://www.cbc.ca/canada/toronto/story/2009/10/26/h1n1-ontario.html. Accessed 04 September 2010

  7. CTV News, Top Stories. H1N1 vaccine hits speed bump, shortages likely. Available at: http://www.ctv.ca/CTVNews/TopStories/20091030/Swine_Vaccine_091030/. Accessed 30 August 2010

  8. The Globe and Mail. Ontario suspends rollout of H1N1 vaccine. Available at: http://www.theglobeandmail.com/life/health/h1n1-swine-flu/ontario-suspends-rollout-of-h1n1-vaccine/article1345884/. Accessed 30 August 2010

  9. Wyatt KN, Ryan GJ, Sheerin KA (2006) Reduced-dose influenza vaccine. Ann Pharmacother 40(9):1635–1639

    Article  PubMed  CAS  Google Scholar 

  10. Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ et al (2008) Half- vs full-dose trivalent inactivated influenza vaccine (2004–2005): age, dose, and sex effects on immune responses. Arch Intern Med 168(22):2405–2414

    Article  PubMed  Google Scholar 

  11. Treanor J, Keitel W, Belshe R, Campbell J, Schiff G, Zangwill K et al (2002) Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 20(7–8):1099–1105

    Article  PubMed  CAS  Google Scholar 

  12. Kramer JS, Durham C, Schroeder T, Garrelts JC (2006) Effectiveness of half-dose versus full-dose influenza vaccine in health care workers. Am J Health Syst Pharm 63(21):2111–2115

    Article  PubMed  Google Scholar 

  13. Food and Drug Administration (FDA) (2009) Regulatory considerations regarding the use of novel influenza A (H1N1) virus vaccines. Vaccines and related biological products advisory committee, July 23, 2009. Available at:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM172424.pdf. Accessed 06 September 2010

  14. World Health Organization (2002) WHO manual on animal influenza diagnosis and surveillance. World Health Organization, Geneva

  15. Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus AD (2004) Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 103(1–2):125–132

    Article  PubMed  CAS  Google Scholar 

  16. Vajo Z, Tamas F, Sinka L, Jankovics I (2010) Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial. Lancet 375(9708):49–55

    Article  PubMed  CAS  Google Scholar 

  17. Jackson LA, Austin G, Chen RT, Stout R, DeStefano F, Gorse GJ et al (2001) Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19(32):4703–4709

    Article  PubMed  CAS  Google Scholar 

  18. Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F et al (2006) Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 166(10):1121–1127

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the staff of the Public Health Laboratory, Ontario Agency of Health Protection and Promotion, for their assistance with this study.

Financial disclosure

This project was supported by a research fellowship of the Swiss National Science Foundation (grant number PBZHP3-125576, http://www.snf.ch/E/Pages/default.aspx) to SPK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests

AM has investigator-initiated research studies funded by GlaxoSmithKline Ltd. and Sanofi Pasteur, both of which manufacture vaccines. All other authors report no conflicts.

Author information

Authors and Affiliations

  1. Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Room 210, Toronto, Ontario, M5G 1X5, Canada

    B. L. Coleman, S. P. Kuster, D. Low, T. Mazzulli & A. McGeer

  2. University of Toronto, Toronto, Ontario, Canada

    B. L. Coleman, J. Gubbay, D. Low, N. Crowcroft, T. Mazzulli & A. McGeer

  3. Ontario Agency of Health Promotion & Protection, Toronto, Ontario, Canada

    J. Gubbay, D. Low, N. Crowcroft & L. Shi

  4. University of British Columbia, Vancouver, British Columbia, Canada

    D. Scheifele

  5. Child & Family Research Institute, Vancouver, British Columbia, Canada

    D. Scheifele

  6. National Microbiology Laboratory, Winnipeg, Mannitoba, Canada

    Y. Li

  7. Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada

    S. A. Halperin

  8. Public Health Agency of Canada, Ottawa, Ontario, Canada

    B. Law

  9. Public Health Agency of Canada—Canadian Institutes of Health Research Influenza Research Network, Ottawa, Ontario, Canada

    D. Scheifele, S. A. Halperin, B. Law & A. McGeer

Authors
  1. B. L. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. P. Kuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Gubbay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Scheifele
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Low
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Crowcroft
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. Mazzulli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. A. Halperin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B. Law
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A. McGeer
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Working Adults Influenza Cohort Study Group

Corresponding author

Correspondence to B. L. Coleman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coleman, B.L., Kuster, S.P., Gubbay, J. et al. Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. Eur J Clin Microbiol Infect Dis 31, 591–597 (2012). https://doi.org/10.1007/s10096-011-1352-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-011-1352-5

Keywords

Search

Navigation